addressing a broad number of regulatory issues. The NOI also referenced the New York Public Service Commission's Petition for Rulemaking Proceeding (Petition), docketed RM98–11–000 regarding rate design. The Commission noted that the concerns raised by New York are similar to the issues raised by the Commission in the NOI, and therefore, should be discussed by commenters in the NOI proceeding, Docket No. RM98–12–000.

In their motion, Petitioners state that the NOPR, Petition, and NOI embrace a vast number of issues that will affect the interstate gas transportation market and create, if promulgated, a comprehensive change in the current way of doing business. The motion also states that because the NOPR and the NOI raise and request comment on legal, policy, operational, and economic issues, additional time is requested to prepare and file comments. On October 6, 1998, the Edison Electric Institute filed an answer in support of the Petitioners motion.

Upon consideration, notice is hereby given that an extension of time of the filing of comments on in the above-docketed proceedings is granted to and including January 22, 1999.

David P. Boergers,

Secretary.

[FR Doc. 98–27805 Filed 10–15–98; 8:45 am]

BILLING CODE 6717–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 216

[Docket No. 98N–0182]

List of Bulk Drug Substances That May Be Used in Pharmacy Compounding; Preliminary Draft Proposed Rule; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Availability of preliminary draft proposed rule.

SUMMARY: The Food and Drug Administration (FDA) is proposing regulations identifying the bulk drug substances that may be used in pharmacy compounding under the exemptions provided by the Federal Food, Drug, and Cosmetic Act (the act) even though they are neither the subject of a current United States Pharmacopeia (USP) or National Formulary (NF) monograph nor a component of an FDA approved drug. FDA's development and publication of this bulk drug list is required by the Food and Drug Administration Modernization Act of 1997 (Modernization Act). This preliminary draft of the proposed rule is being made available to allow full discussion of its contents at the Pharmacy Compounding Advisory Committee meeting to be held on October 14, 15, and 16, 1998. FDA is requesting comments concerning the preliminary draft of the proposed rule.

DATES: Submit written comments on or before October 30, 1998.

ADDRESSES: A copy of the preliminary draft proposed rule will be on display at the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit requests for copies of the preliminary draft proposed rule from the Drug Information Branch (HFD–210), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4573, and the Center for Drug Evaluation and Research's Fax-on-Demand system at 301–827–0577 or 800–342–2722. An electronic version of the preliminary draft proposed rule is available via the Internet at ''http://www.fda.gov/cder/fdama'' under the subject ''Pharmacy Compounding.''

FOR FURTHER INFORMATION CONTACT: Robert J. Tonelli, Center for Drug Evaluation and Research (HFD–332), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–7295.

SUPPLEMENTARY INFORMATION:

I. Background

On November 21, 1997, the President signed the Modernization Act (Pub. L. 105–115) into law. Section 127 of the Modernization Act, which adds section 503A to the act (21 U.S.C. 353a), clarifies the status of pharmacy compounding under Federal law.

Section 503A(d)(1) of the the act requires that, unless good cause is shown, FDA convene and consult with an advisory committee on compounding before issuing regulations listing bulk drug substances that may be used in pharmacy compounding. The Pharmacy Compounding Advisory Committee was established by a final rule published in the **Federal Register** of March 10, 1998 (63 FR 11596). A meeting of the advisory committee to discuss, among other things, the list of bulk drug substances that may be used in pharmacy compounding was announced in the **Federal Register** of September 4, 1998 (63 FR 47301). The meeting will be held on October 14, 15, and 16, 1998.

Under 21 CFR 10.40(f)(4) and 10.80(b)(2), FDA has decided to make available to the public a preliminary draft proposed rule identifying the bulk drug substances that may be used in pharmacy compounding under the exemptions provided by the act even though they are neither the subject of a current USP or NF monograph nor a component of an FDA approved drug. This preliminary draft proposed rule is being made available to facilitate a full and open discussion at the advisory committee meeting of the list of bulk drug substances that may be used in pharmacy compounding.

II. Request for Comments

Interested persons may, on or before October 30, 1998, submit to the Dockets Management Branch (address above) written comments regarding this preliminary draft proposed rule. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

(Authority: 21 U.S.C. 321 *et seq.*)

Dated: October 7, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–27814 Filed 10–13–98; 2:28 pm]

BILLING CODE 4160–01–F

DEPARTMENT OF THE TREASURY

Internal Revenue Service

26 CFR Part 1

[REG–110332–98]

RIN–1545–AW43

Conversion to the Euro; Hearing Cancellation

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Cancellation of notice of public hearing on proposed regulations.

SUMMARY: This document provides notice of cancellation of a public hearing on proposed regulations relating to the change to the euro.

DATES: The public hearing originally scheduled for Tuesday, October 20, 1998, beginning at 10 a.m. is cancelled.

FOR FURTHER INFORMATION CONTACT: LaNita Van Dyke of the Regulations Unit, Assistant Chief Counsel (Corporate), (202) 622–7190, (not a toll-free number).

SUPPLEMENTARY INFORMATION: The subject of the public hearing is proposed

regulations under sections 985 and 1001 of the Internal Revenue Code. A notice of proposed rulemaking and notice of public hearing appearing in the **Federal Register** on Wednesday, July 29, 1998 (63 FR 40383), announced that the public hearing on proposed regulations under sections 985 and 1001 of the Internal Revenue Code would be held on Tuesday, October 20, 1998, beginning at 10 a.m., in room 2615, Internal Revenue Building, 1111 Constitution Avenue, NW., Washington DC.

The public hearing scheduled for Tuesday, October 20, 1998, is cancelled.

Cynthia E. Grigsby,

Chief, Regulations Unit, Assistant Chief Counsel (Corporate).

[FR Doc. 98–27753 Filed 10–15–98; 8:45 am]

BILLING CODE 4830–01–U

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Parts 180 and 185

[OPP–300734; FRL–6035–7]

RIN 2070–AB78

Pesticides Tolerance Reassessment Actions; 4-Amino-6-(1,1-dimethylethyl)-3-(methylthio)-1,2,4-triazin-5(4H)-one [Metribuzin], Dichlobenil, Diphenylamine, O-Ethyl O-[4-(methylthio) phenyl] S-propyl phosphorodithioate [Sulprofos], Pendimethalin, and Terbacil

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: This document announces the proposed revocation of tolerances for the herbicides 4-amino-6-(1,1-dimethylethyl)-3-(methylthio)-1,2,4-triazin-5(4H)-one [Metribuzin], dichlobenil, pendimethalin, and terbacil; and the insecticide O-ethyl O-[4-(methylthio) phenyl] S-propyl phosphorodithioate [Sulprofos]. EPA expects to determine whether any individuals or groups want to support these tolerances. Also, this document is proposing the establishment and revision of tolerances for 4-amino-6-(1,1-dimethylethyl)-3-(methylthio)-1,2,4-triazin-5(4H)-one (metribuzin), dichlobenil, pendimethalin, terbacil, and the plant growth regulator diphenylamine. In addition, EPA is also proposing to revise commodity terminology for 4-amino-6-(1,1-dimethylethyl)-3-(methylthio)-1,2,4-triazin-5(4H)-one [Metribuzin], diphenylamine, and pendimethalin to conform to current practice. The regulatory actions in this notice are part of the Agency's reregistration program under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), and the tolerance reassessment requirements of the Federal Food, Drug, and Cosmetic Act (FFDCA). By law, EPA is required to reassess 33% of the tolerances in existence on August 2, 1996, by August 1999, or about 3,200 tolerances.

DATES: Comments must be received on or before December 15, 1998.

ADDRESSES: Comments may be submitted by mail, electronically, or in person. Please follow the detailed instructions for each method as provided in Unit IV of the ''SUPPLEMENTARY INFORMATION'' section of this document. Be sure to identify the appropriate docket number [OPP–300734].

FOR FURTHER INFORMATION CONTACT: For technical information contact: Joseph Nevola, Special Review Branch, (7508C), Special Review and Reregistration Division, Office of Pesticide Programs, U.S. Environmental Protection Agency, 401 M St., S.W., Washington, DC 20460. Office location: Special Review Branch, Crystal Mall #2, 6th floor, 1921 Jefferson Davis Hwy., Arlington, VA. Telephone: (703) 308-8037; e-mail: nevola.joseph@epa.gov.

SUPPLEMENTARY INFORMATION:

I. What is the progress of tolerance reassessment?

By law, EPA is required to reassess 33% of the tolerances in existence on August 2, 1996, by August 1999, or about 3,200 tolerances. The regulatory actions proposed in this document pertain to the provosed revocation of 29 tolerances and/or exemptions, which count toward the August, 1999 review deadline of FIFRA, as amended by the Food Quality Protection Act (FQPA) of 1996.

II. Does this notice apply to me?

You may be affected by this notice if you sell, distribute, manufacture, or use pesticides for agricultural applications, process food, distribute or sell food, or implement governmental pesticide regulations. Pesticide reregistration and other actions [see FIFRA section 4(g)(2)] include tolerance and exemption reassessment under FFDCA section 408. In this notice, the tolerance actions are proposed in coordination with the cancellation of associated registrations. Potentially affected categories and entities may include, but are not limited to:

Category	Examples of Potentially Affected Entities
Agricultural Stakeholders.	Growers/Agricultural Workers Contractors [Certified/Commercial Applicators, Handlers, Advisors, etc.] Commercial Processors Pesticide Manufacturers User Groups Food Consumers
Food Distributors ...	Wholesale Contractors Retail Vendors Commercial Traders/Importers
Intergovernmental Stakeholders.	State, Local, and/or Tribal Government Agencies
Foreign Entities	Governments, Growers, Trade Groups

This table is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be affected by this action. Other types of entities not listed in this table could also be affected. If you have any questions regarding the applicability of this action to a particular entity, you can consult with the technical person listed in the ''FOR FURTHER INFORMATION CONTACT'' section.

III. How can I get additional information or copies of this or other support documents?

A. Electronically

You may obtain electronic copies of this document and various support documents from the EPA Internet Home Page at http://www.epa.gov/. On the Home Page select ''Laws and Regulations'' and then look up the entry for this document under ''Federal Register - Environmental Documents.'' You can also go directly to the ''Federal Register'' listings at http://www.epa.gov/homepage/fedrgstr/.

B. In Person or by Phone

If you have any questions or need additional information about this action, please contact the technical person identified in the ''FOR FURTHER INFORMATION CONTACT'' section. In addition, the official record for this notice, including the public version, has been established under docket control number [OPP–300734], (including comments and data submitted electronically as described below). A public version of this record, including printed, paper versions of any electronic comments, which does not include any information claimed as Confidential Business Information (CBI), is available for inspection in Room 119, Crystal Mall